{"entity":{"id":"nct05991583","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of IBB0979 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","summary":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05991583 by SUNHO（China）BioPharmaceutical CO., Ltd., with 25 participants planned, started 2023-07-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: IBB0979.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05991583","url":"https://clinicaltrials.gov/study/NCT05991583"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05991583","phase":"1/2","setting":"A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBB0979 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","enrolled":25,"outcomes":[]},"route":"/trials/nct05991583/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}